Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021.

Autores de IIS La Fe

• Miguel Masia Massoni

  Autor

• Marta Montero Alonso

  Autor

Participantes ajenos a IIS La Fe

• Vinuela, Laura
• de Salazar, Adolfo
• Fuentes, Ana
• Serrano-Conde, Esther
• Falces-Romero, Iker
• Pinto, Adriana
• Portilla, Irene
• Peraire, Joaquim
• Gomez-Sirvent, Juan Luis
• Sanchiz, Marta
• Iborra, Asuncion
• Baza, Begona
• Aguilera, Antonio
• Olalla, Julian
• Espinosa, Nuria
• Iribarren, Jose Antonio
• Martinez-Velasco, Marina
• Imaz, Arkaitz
• Rivero, Maria
• Suarez-Garcia, Ines
• Macia, Maria Dolores
• Galan, Juan Carlos
• Perez-Elias, Maria Jesus
• Garcia-Fraile, Lucio Jesus
• Moreno, Cristina
• Garcia, Federico

Grupos

• Investigacion clínica en enfermedades crónicas e Infección por el VIH

Abstract

To evaluate the prevalence of transmitted drug resistance (TDR)to nucleoside and nonnucleoside reverse transcriptase inhibitors (NRTI,NNRTI),protease inhibitors (PI),and integrase strand transfer inhibitors (INSTI)in Spain during the period 2019-2021, as well as to evaluate transmitted clinically relevant resistance (TCRR)to antiretroviral drugs. Reverse transcriptase (RT),protease (Pro), and Integrase (IN)sequences from 1824 PLWH (people living with HIV) were studied. To evaluate TDR we investigated the prevalence of surveillance drug resistance mutations (SDRM).To evaluate TCRR (any resistance level=3), and for HIV subtyping we used the Stanford v.9.4.1 HIVDB Algorithm and an in-depth phylogenetic analysis. The prevalence of NRTI SDRMs was 3.8% (95% CI,2.8%-4.6%), 6.1% (95% CI,5.0%-7.3%) for NNRTI, 0.9% (95% CI,0.5%-1.4%) for PI, and 0.2% (95% CI,0.0%-0.9%) for INSTI. The prevalence of TCRR to NRTI was 2.1% (95% CI,1.5%-2.9%), 11.8% for NNRTI, (95% CI,10.3%-13.5%), 0.2% (95% CI,0.1%-0.6%) for PI, and 2.5% (95% CI,1.5%-4.1%) for INSTI. Most of the patients were infected by subtype B (79.8%), while the majority of non-Bs were CRF02_AG (n=109, 6%). The prevalence of INSTI and PI resistance in Spain during the period 2019-2021 is low, while NRTI resistance is moderate, and NNRTI resistance is the highest. Our results support the use of integrase inhibitors as first-line treatment in Spain. Our findings highlight the importance of ongoing surveillance of TDR to antiretroviral drugs in PLWHparticularly with regard to first-line antiretroviral therapy.

© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Keywords

• HIV; TDR; clinical resistance; transmission